Europe Newborn Screening Market Size & Outlook, 2023-2030
Europe newborn screening market, 2018-2030 (US$M)
Related Markets
Europe newborn screening market highlights
- The Europe newborn screening market generated a revenue of USD 206.4 million in 2023.
- The market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
- In terms of segment, tandem mass spectrometry was the largest revenue generating technology in 2023.
- Electrophoresis is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, Italy is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 206.4 million |
| Market revenue in 2030 | USD 324.6 million |
| Growth rate | 6.7% (CAGR from 2023 to 2030) |
| Largest segment | Tandem mass spectrometry |
| Fastest growing segment | Electrophoresis |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-based Assay, DNA Assays, Electrophoresis |
| Key market players worldwide | Bio-Rad Laboratories Inc, Agilent Technologies, Agilent Technologies Inc, Covidien, Masimo Corp, Waters Corp, Natus Medical, GE HealthCare Technologies Inc Common Stock, PerkinElmer, Danaher Corp |
Other key industry trends
- In terms of revenue, Europe region accounted for 25.9% of the global newborn screening market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 451.1 million by 2030.
Tandem mass spectrometry was the largest segment with a revenue share of 24.71% in 2023. Horizon Databook has segmented the Europe newborn screening market based on tandem mass spectrometry, pulse oximetry, enzyme-based assay, dna assays, electrophoresis covering the revenue growth of each sub-segment from 2018 to 2030.
The Newborn Screening (NBS) program is followed across all the European countries. However, alteration in the list of tests and rare disease inclusion by the European Commission has led to preparation of new policies that are in line with the recommendations and requirement of the region. EURORDIS functions as the voice for representing the needs of patients and families within the region.
The European Surveillance of Congenital Anomalies (EUROCAT), established in 1979, maintains registry of epidemiology and evaluates development in pre-natal and newborn screening. According to data published by EUROCAT, over 1.7 million births are screened annually from across 23 countries of EU.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Newborn Screening Market Scope
Newborn Screening Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe newborn screening market size, by country, 2018-2030 (US$M)
Europe Newborn Screening Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
